Individualized Cancer Therapy, Future Approaches / Da-Yong Lu, Ting-Ren Lu, Bin Xu, Jin-Yu Che, Ying Shen, Nagendra Sastry Yarla
Background: Cancer is a series of different disease (>200 different sub-types) with an identical feature of unlimited growth, invasive and multi-step/multi-level metastasis processes. Objective: Individualized cancer therapies/personalized cancer therapies will undergo a dramatic evolution to cope with this disease diversity and a complexity of tumor genes/biomarkers. Methods: The next generation of personalized cancer therapy must simultaneously contain information of pharmacology (drug sensitivity or drug combination), oncology (tumor etiopathological information), computational network (predictive of cancer risks and therapeutic efficacy), toxicology (adverse side-effects and human mortality), artificial intelligence and patient’s desire (decision-aid), especially technology merge. Results: Future multi-functional approach is inevitable. After all, multi-functional personalized cancer therapy (collective and balanced regime/paradigms) might take formation in the future. Conclusion: A reliable, safe, effective and collective platform can be established through further scientific and technical approaches in the clinic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Current pharmacogenomics and personalized medicine - 16(2018), 2, Seite 156- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lu, Da-Yong [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (8 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL009084452 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL009084452 | ||
| 003 | DE-627 | ||
| 005 | 20231129095707.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220323s2018 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL009084452 | ||
| 035 | |a (KFL)prod_DARH_.3AD5BF44F6D39F96339FFEC9A354195A0F8C1BD8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Lu, Da-Yong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Individualized Cancer Therapy, Future Approaches |c Da-Yong Lu, Ting-Ren Lu, Bin Xu, Jin-Yu Che, Ying Shen, Nagendra Sastry Yarla |
| 264 | 1 | |c 2018 | |
| 300 | |a 1 Online-Ressource (8 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: Cancer is a series of different disease (>200 different sub-types) with an identical feature of unlimited growth, invasive and multi-step/multi-level metastasis processes. Objective: Individualized cancer therapies/personalized cancer therapies will undergo a dramatic evolution to cope with this disease diversity and a complexity of tumor genes/biomarkers. Methods: The next generation of personalized cancer therapy must simultaneously contain information of pharmacology (drug sensitivity or drug combination), oncology (tumor etiopathological information), computational network (predictive of cancer risks and therapeutic efficacy), toxicology (adverse side-effects and human mortality), artificial intelligence and patient’s desire (decision-aid), especially technology merge. Results: Future multi-functional approach is inevitable. After all, multi-functional personalized cancer therapy (collective and balanced regime/paradigms) might take formation in the future. Conclusion: A reliable, safe, effective and collective platform can be established through further scientific and technical approaches in the clinic | ||
| 700 | 1 | |a Lu, Ting-Ren |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Che, Jin-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Yarla, Nagendra Sastry |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmacogenomics and personalized medicine |d Sharjah : Bentham, 2008 |g 16(2018), 2, Seite 156- |h Online-Ressource |w (DE-627)KFL000006556 |w (DE-600)2424232-9 |w (DE-576)30683636X |x 1875-6913 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2018 |g number:2 |g pages:156- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1875-6921&volume=16&issue=2&spage=156 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_DARH_01 | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2018 |e 2 |h 156- | ||